[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5650235A2 - Derivados de imidazol - Google Patents

Derivados de imidazol

Info

Publication number
CO5650235A2
CO5650235A2 CO06019310A CO06019310A CO5650235A2 CO 5650235 A2 CO5650235 A2 CO 5650235A2 CO 06019310 A CO06019310 A CO 06019310A CO 06019310 A CO06019310 A CO 06019310A CO 5650235 A2 CO5650235 A2 CO 5650235A2
Authority
CO
Colombia
Prior art keywords
lower alkyl
halogen
cyano
compound
hydrogen
Prior art date
Application number
CO06019310A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Porter Richard Hugh Phillip
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5650235A2 publication Critical patent/CO5650235A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula general en la que R1 significa halógeno, alquilo inferior, alcoxi inferior, CF3 o ciano;R2 significa arilo o heteroarilo, opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por alquilo inferior, halógeno, alcoxi inferior, CF3 y ciano;R3 significa hidrógeno, C(O)H o CH2R5, en el que R5 es hidrógeno, OH, alquilo C1-C6 o cicloalquilo C3-C12;R4 significa alquilo inferior o cicloalquilo C3-C12;X significa N o CH;Y significa - (CHR) 1, 2 ó 3 R significa hidrógeno o alquilo inferior;así como las sales farmacéuticamente aceptables del mismo.2.- Un compuesto de la fórmula I según la reivindicación 1, en la que R1, R2, R3, X, Y y R tienen los significados definidos en la reivindicación 1 y R4 es alquilo inferior.3.- Un compuesto de la fórmula I según la reivindicación 1, en la que R1 significa halógeno, alquilo inferior, alcoxi inferior, CF3 o ciano; R2 significa arilo o heteroarilo, opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por alquilo inferior, halógeno, alcoxi inferior, CF3 y ciano; R3 significa H;R4 significa metilo;X significa N o CH;Y significa - (CHR) 1, 2 ó 3 R significa hidrógeno o alquilo inferior;así como las sales farmacéuticamente aceptables del mismo.4.- Un compuesto de la fórmula I según la reivindicación 1, en la que R1, R3, R4, Y y R tienen los significados definidos en la reivindicación 1; X es CH y R2 es piridilo, opcionalmente sustituido por alquilo inferior o halógeno.
CO06019310A 2003-09-04 2006-02-27 Derivados de imidazol CO5650235A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019604 2003-09-04

Publications (1)

Publication Number Publication Date
CO5650235A2 true CO5650235A2 (es) 2006-06-30

Family

ID=34224067

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06019310A CO5650235A2 (es) 2003-09-04 2006-02-27 Derivados de imidazol

Country Status (21)

Country Link
US (2) US7452909B2 (es)
EP (1) EP1831193B1 (es)
JP (1) JP4490423B2 (es)
KR (2) KR100811898B1 (es)
CN (1) CN1875016B (es)
AR (1) AR045548A1 (es)
AT (1) ATE427945T1 (es)
AU (1) AU2004270352B2 (es)
BR (1) BRPI0414148A (es)
CA (1) CA2537826C (es)
CO (1) CO5650235A2 (es)
DE (1) DE602004020525D1 (es)
ES (1) ES2321408T3 (es)
IL (1) IL173911A (es)
MX (1) MXPA06002453A (es)
NO (1) NO20061045L (es)
RU (1) RU2345074C2 (es)
SG (1) SG146627A1 (es)
TW (1) TWI290138B (es)
WO (1) WO2005023795A1 (es)
ZA (1) ZA200601865B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8204149B2 (en) 2003-12-17 2012-06-19 Qualcomm Incorporated Spatial spreading in a multi-antenna communication system
US8169889B2 (en) 2004-02-18 2012-05-01 Qualcomm Incorporated Transmit diversity and spatial spreading for an OFDM-based multi-antenna communication system
US8923785B2 (en) 2004-05-07 2014-12-30 Qualcomm Incorporated Continuous beamforming for a MIMO-OFDM system
PT1756086E (pt) * 2004-06-01 2008-08-08 Hoffmann La Roche Piridin-4-il-etinil-imidazoles e pirazoles como antagonistas dos receptores mglu5
ATE397601T1 (de) * 2004-06-01 2008-06-15 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
US7978649B2 (en) 2004-07-15 2011-07-12 Qualcomm, Incorporated Unified MIMO transmission and reception
US8543070B2 (en) 2006-04-24 2013-09-24 Qualcomm Incorporated Reduced complexity beam-steered MIMO OFDM system
EP2125779B1 (en) 2006-12-21 2016-04-27 F. Hoffmann-La Roche AG Polymorphs of a mglur5 receptor antagonist
WO2009097414A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Use of imidazolylalkyl-pyridines for the treatment of addictive disorders
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52709A1 (en) * 1989-06-30 1998-09-28 Du Pont Substituted imidazoles
EP1214303A1 (en) 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
CA2470612A1 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
BRPI0411350A (pt) * 2003-06-12 2006-07-11 Hoffmann La Roche derivados de imidazol substituìdos por heteroarilas como antagonistas de receptores de glutamato
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
WO2005023795A1 (en) 2005-03-17
JP2007504188A (ja) 2007-03-01
CN1875016A (zh) 2006-12-06
AR045548A1 (es) 2005-11-02
AU2004270352B2 (en) 2011-02-24
CN1875016B (zh) 2011-06-01
US7452909B2 (en) 2008-11-18
NO20061045L (no) 2006-03-31
TW200517382A (en) 2005-06-01
SG146627A1 (en) 2008-10-30
JP4490423B2 (ja) 2010-06-23
KR20060037460A (ko) 2006-05-03
DE602004020525D1 (en) 2009-05-20
IL173911A (en) 2012-07-31
MXPA06002453A (es) 2006-06-20
EP1831193A1 (en) 2007-09-12
ES2321408T3 (es) 2009-06-05
CA2537826C (en) 2012-04-17
KR100893957B1 (ko) 2009-04-20
US7964620B2 (en) 2011-06-21
AU2004270352A1 (en) 2005-03-17
ATE427945T1 (de) 2009-04-15
BRPI0414148A (pt) 2006-10-31
US20050054686A1 (en) 2005-03-10
EP1831193B1 (en) 2009-04-08
RU2345074C2 (ru) 2009-01-27
RU2006110537A (ru) 2007-10-10
KR20070113325A (ko) 2007-11-28
TWI290138B (en) 2007-11-21
CA2537826A1 (en) 2005-03-17
US20090018171A1 (en) 2009-01-15
KR100811898B1 (ko) 2008-03-10
IL173911A0 (en) 2006-07-05
ZA200601865B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
CO5650235A2 (es) Derivados de imidazol
ES2624795T3 (es) Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR049739A1 (es) Derivados de aril-piridina
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR073136A1 (es) Compuestos de pirrol
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
AR046625A1 (es) Derivados de pirazol y composiciones farmaceuticas.
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
CO6241119A2 (es) Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
WO2008136444A1 (ja) 縮合複素環誘導体
CO6400145A2 (es) Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b

Legal Events

Date Code Title Description
FC Application refused